☰

Heather A. Hirsch, Ph.D. - Publications

Affiliations: 
2003 Michigan State University, East Lansing, MI 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Hirsch HA, Reeves J, Zi T, Deshpande A, Yang G, Needham A, Shu J, Khattri A, Brisson RJ, Tan C, Harvey C, Law D, Michaelson J, Trehu EG, Sathyanarayanan S, et al. Biomarker-driven indication selection in JTX-2011 ICONIC clinical trial. Journal of Clinical Oncology. 35: 11602-11602. DOI: 10.1200/Jco.2017.35.15_Suppl.11602  0.371
2017 Haines BB, Javaid S, Cui L, Hirsch H, Cemerski S, McClanahan T, Sathe M, Zhang S, Rosenzweig M, Long B, Malefyt RdW. Abstract 4714: Blockade of LAG-3 amplifies immune activation signatures and augments curative antitumor responses to anti-PD-1 therapy in immune competent mouse models of cancer Cancer Research. 77: 4714-4714. DOI: 10.1158/1538-7445.Am2017-4714  0.371
2016 Hirsch H, Mangadu R, Cai M, Ma Y, Phan U, Wang Y, Sriram V, Phillips JH, McClanahan T, Long B, Pinheiro EM. Abstract B114: Evaluation of the antitumor activity and molecular characterization of mouse syngeneic tumor models in response to anti-PD-1 treatment as a single agent and in combination with approved agents Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B114  0.352
2016 Deshpande A, Growdon WB, Hirsch H, Zi T, Grange C, Reeves J, Stall J, Rueda B, Sathyanarayanan S. Abstract A052: Characterization of immune regulatory molecules B7-H4, PD-L1, and ICOS in micro-satellite stable (MSS) and micro-satellite instable (MSI) endometrial tumors Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A052  0.343
2016 Pinheiro EM, Hinton M, Mangadu R, Cai M, Phan U, Nebozhyn M, Hirsch H, Loboda A, Javaid S, Wang Y, Sriram V, Phillips JH, McClanahan T, Long B. Abstract 543: Preclinical combination strategies to enhance the efficacy of the anti-PD-1 antibody pembrolizumab Cancer Research. 76: 543-543. DOI: 10.1158/1538-7445.Am2016-543  0.322
2015 Pinheiro EM, Mangadu R, Phan UT, Cai M, Ma Y, Hirsch HA, McClanahan TK, Moniz RJ, Al-Assaad A, Basu S, Wang Y, Sriram V, Phillips JH, Long BJ. Abstract 269: Evaluation of the antitumor activity of anti-PD-1 immunotherapy as a single agent and in combination with approved agents in preclinical tumor models Cancer Research. 75: 269-269. DOI: 10.1158/1538-7445.Am2015-269  0.329
2015 Hirsch HA, Pinheiro EM, Cai M, Ma Y, Sathe M, Ayers M, McClanahan TK. Abstract 1328: Molecular characterization of mouse syngeneic tumor models in response to treatment with anti-PD-1 immunotherapy Cancer Research. 75: 1328-1328. DOI: 10.1158/1538-7445.Am2015-1328  0.375
2015 Ayers MD, Nebozhyn M, Hirsch HA, Cristescu R, Murphy EE, Kang SP, Ebbinghaus SW, McClanahan TK, Loboda A, Lunceford JK. Abstract 1307: Assessment of gene expression in peripheral blood from patients with advanced melanoma using RNA-seq before and after treatment with anti-PD-1 therapy with pembrolizumab (MK-3475) Cancer Research. 75: 1307-1307. DOI: 10.1158/1538-7445.Am2015-1307  0.401
2014 Muvaffak A, Pan Q, Yan H, Fernandez R, Lim J, Dolinski B, Nguyen TT, Strack P, Wu S, Chung R, Zhang W, Hulton C, Ripley S, Hirsch H, Nagashima K, et al. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Molecular Cancer Research : McR. 12: 1055-66. PMID 24752990 DOI: 10.1158/1541-7786.Mcr-13-0642  0.323
2013 Hatch H, Booher R, Perera S, Nguyen T, Dolinski B, Al-Assaad S, Harmonay L, Schuller A, Angagaw M, Long B, Qu X, Miselis N, Ayers M, Nebozhyn M, Hirsch H, et al. Abstract 698: MCL1 dependent cells are sensitive to the CDK inhibitor Dinaciclib. Cancer Research. 73: 698-698. DOI: 10.1158/1538-7445.Am2013-698  0.332
2012 Booher R, Hirsch H, Strack P, Zawel L, Fawell S. Abstract 3063: Mcl-1 dependency is a predictive biomarker for apoptotic induction by short-term dinaciclib (SCH 727965) treatment Cancer Research. 72: 3063-3063. DOI: 10.1158/1538-7445.Am2012-3063  0.384
2007 Ghosh S, Hirsch HA, Sekinger EA, Kapranov P, Struhl K, Gingeras TR. Differential analysis for high density tiling microarray data. Bmc Bioinformatics. 8: 359. PMID 17892592 DOI: 10.1186/1471-2105-8-359  0.32
2004 Hirsch HA, Jawdekar GW, Lee KA, Gu L, Henry RW. Distinct mechanisms for repression of RNA polymerase III transcription by the retinoblastoma tumor suppressor protein. Molecular and Cellular Biology. 24: 5989-99. PMID 15199152 DOI: 10.1128/Mcb.24.13.5989-5999.2004  0.472
2003 Hinkley CS, Hirsch HA, Gu L, LaMere B, Henry RW. The small nuclear RNA-activating protein 190 Myb DNA binding domain stimulates TATA box-binding protein-TATA box recognition. The Journal of Biological Chemistry. 278: 18649-57. PMID 12621023 DOI: 10.1074/Jbc.M204247200  0.692
2000 Hirsch HA, Gu L, Henry RW. The retinoblastoma tumor suppressor protein targets distinct general transcription factors to regulate RNA polymerase III gene expression. Molecular and Cellular Biology. 20: 9182-91. PMID 11094070 DOI: 10.1128/Mcb.20.24.9182-9191.2000  0.737
Show low-probability matches.